BFRI (Biofrontera) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


BFRI Biofrontera Inc BFRI
44 GF Score
Price $1.00
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Biofrontera's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

BFRI vs AKAN, CABR, BIOE: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Biofrontera's Margin of Safety % (DCF FCF Based) falls into.


BFRI
44GF Score
Biofrontera Inc BFRI
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $1.00 is trading 85.2% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.54 vs. price of $1.00 (85.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.54
GF Value